An estimated 166,400 new cases of cancer will occur in Canada in
2008. Bone metastases unfortunately remain a common site of
recurrence, with breast and prostate cancer patients representing a
substantial proportion of this population. Metastatic bone disease
is associated with significant morbidity and mortality. Pain is
experienced by up to two thirds of patients. The prognosis for
patients with bone metastases is highly influenced by tumour type,
performance status, and the presence of extraosseous disease. The
median survival has been significantly longer in breast cancer
patients with a first relapse in the axial skeleton (24 months)
versus patients with initial relapse in the liver (3 months) (2).
Survival after diagnosis of bone metastases is influenced by the
subsequent development of extraosseous metastatic sites: 1.6 years
versus 2.1 years in patients with bone-only disease.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!